FRONTIER BIOTECHNOLOGIES CO.Inc.

Product

Long-acting peptide drug discovery and development platform
HOME>Product


Albuvirtide is a treatment-paradigm shifting long-acting HIV fusion inhibitor for treatment of HIV infection and AIDS. An NDA was accepted by China FDA in July 2016. It could become world's first long-acting anti-HIV new drug ever approved. Albuvirtide could potentially enhance patient compliance, improve quality of life and reduce treatment cost for both drug-experienced and drug-naive HIV-infected patients.


Albuvirtide
Product overview

Albuvirtide is a treatment-paradigm shifting long-acting HIV fusion inhibitor for treatment of HIV infection and AIDS.

Develop innovative therapies to better human lives